Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States-Reference-Cited by-同舟云学术

Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States

Published:2023-02-25 Issue:3 Volume:7 Page:393-404
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Sepassi Aryana^ORCID,Saunders Ila M.,Bounthavong Mark,Taplitz Randy A.,Logan Cathy,Watanabe Jonathan H.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00398-y.pdf

Reference55 articles.

1. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haematopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-127.

2. Huang YT, Neofytos D, Foldi J, et al. Cytomegalovirus infection after CD34(+)-selected hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(8):1480–6.

3. Milano F, Pergam SA, Xie H, et al. Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood. 2011;118(20):5689–96.

4. De Latour RP, Chevallier P, Blaise D, et al. Clinical and economic impact of treatment CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation. J Med Virol. 2020;92(12):3665–73.

5. McBride J, Sheinson D, Jiang J, et al. Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients. Open Forum Infect Dis. 2019;6(2):003.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2024-08

2. Clinical and Economic Impact of CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation: Perspectives from a Middle‐Income Nation;Clinical Transplantation;2024-06

3. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis;Turkish Journal of Hematology;2024-03-04

4. Current and Emerging Antiviral Agents in the Prevention and Treatment of Cytomegalovirus in Pediatric Transplant Recipients;Journal of the Pediatric Infectious Diseases Society;2024-02-01

5. Letermovir Prophylaxis After Kidney Transplantation: Another Tool but Not a Revolution Yet;Transplantation;2023-12-13